NHS Framework Agreement for Branded Medicines - Proprietary Category Tender

NHS England · awarded 24 March 2025 · delivered in East Midlands

£1.2bn Award value £1,241,520,444

72 Suppliers Size not recorded

30 Apr 2029 Runs until from 1 May 2025

Who

Buyer	NHS England Runcorn
Suppliers	Abbvie Ltd Accord-UK Ltd Alissa Healthcare Research Limited Aspen Pharmacare UK Limited Aspire Pharma Limited Astellas Pharma Ltd Aventis Pharma ltd t/a Sanofi Baxter Healthcare Ltd Bayer Plc Besins Healthcare UK LTD BioCryst Ireland Limited CSL Behring UK Ltd CST Pharma Limited Celix Pharma Ltd. Chiesi Limited Colonis Pharma Ltd Day Lewis Medical Ltd Dexcel Pharma Ltd Drugsrus Ltd Eisai Ltd Essential Pharma Esteve Pharmaceuticals Ltd FLYNN PHARMA LTD Ferring Pharmaceuticals Ltd G.L. Pharma UK Limited Galen Limited Gedeon Richter UK Ltd Glenmark Pharmaceuticals Europe Limited Grunenthal INFECTOPHARM LTD Ipsen Janssen-Cilag Ltd Kyowa Kirin International UK New Co Ltd Lupin Healthcare (UK) Limited Merck Serono Limited Mercury Pharmaceuticals Limited Merz Morningside Pharmaeuticals Mylan Napp Pharmaceuticals Ltd Neon Healthcare Ltd Neuraxpharm UK Ltd Nordic Pharma Norgine Pharmaceuticals Limited Novartis Pharmaceuticals UK Ltd Novo Nordisk Organon Pharmaceuticals UK Ltd Orifarm UK Otsuka Pharmaceuticals UK Limited Pfizer Ltd Pharmasure Pharming Group Provepharm UK Ltd ROVI Biotech Ltd Rayner Surgical Group Ltd Recordati Rare Diseases UK Ltd Ridge Pharma SERB SA Sandoz Ltd Selective Supplies Ltd. Strandhaven Ltd t/a Somex Pharma Sun Pharma UK Ltd Synchrony Takeda UK Ltd Teva UK Limited Theramex HQ UK Thornton and Ross Ltd Tillomed Laboratories ltd Wockhardt UK Limited Xiromed Zentiva Pharma UK Ltd medac Pharma LLP
Category	goods
Classification	Pharmaceutical products CPV 33600000
Notice published	22 April 2025

What it is for

Invitation to offer for NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 01 May 2025 Offer reference number: CM/PHR/22/5683 NHS Framework Agreement for Branded Medicines - Proprietary Category Tender: Period of Framework Agreement: 01 May 2025 to 30 April 2029

Read the original award notice on Contracts Finder →

Other contracts from this buyer

1269 awards on file, worth £50.2bn.

Awarded	What for	Buyer	Supplier	Value
4 Mar 2026	New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland	NHS England	Willmott Dixon Construction Limited +9	£37.0bn
24 Mar 2025	NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands	NHS England	CSL Behring UK Ltd +71	£1.2bn
1 Jul 2025	NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025	NHS England	Biogen +20	£986.3m
19 Dec 2024	NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland	NHS England	CSL Behring UK Ltd +5	£905.2m
31 May 2024	NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands	NHS England	Pfizer Ltd +8	£765.0m

Everything NHS England has awarded →

Other contracts won by this supplier

5 awards on file, worth £2.9bn.

Awarded	What for	Buyer	Supplier	Value
24 Mar 2025	NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands	NHS England	CSL Behring UK Ltd +71	£1.2bn
19 Dec 2024	NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland	NHS England	CSL Behring UK Ltd +5	£905.2m
31 May 2024	NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands	NHS England	Pfizer Ltd +8	£765.0m
1 Jan 2025	CSL Behring - Blood Disorder Treatment products (inc Haemophilia A & B)East of England	Norfolk and Norwich University Hospitals NHS…	CSL BEHRING UK LIMITED	£416k
12 Jun 2026	Beriplex	The Christie NHS Foundation Trust	CSL BEHRING UK LIMITED	£12k

Everything CSL Behring UK Ltd has won →